Alnylam Pharmaceuticals
ALNY
$488.31
Share price
-3.35%
Change (1 day)
92.72%
Change (1 year)
Categories
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.
Revenue for Alnylam Pharmaceuticals (ALNY)
Revenue in 2024 (TTM): NZ$3.75 Billion
According to Alnylam Pharmaceuticals
's latest financial reports the company's current revenue (TTM 
) is NZ$3.90 Billion. an increase over the revenue in the year 2023 that were of NZ$2.89 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Alnylam Pharmaceuticals from 2004 to 2024
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2024 | NZ$3.98 B | 37.89% |
| 2023 | NZ$2.89 B | 76.93% |
| 2022 | NZ$1.63 B | 32.19% |
| 2021 | NZ$1.23 B | 80.96% |
| 2020 | NZ$0.68 B | 109.34% |
| 2019 | NZ$0.32 B | 192.18% |
| 2018 | NZ$0.11 B | -11.79% |
| 2017 | NZ$0.12 B | 85.96% |
| 2016 | NZ$68.08 M | 13.38% |
| 2015 | NZ$60.04 M | -6.95% |
| 2014 | NZ$64.53 M | 12.43% |
| 2013 | NZ$57.39 M | -29.24% |
| 2012 | NZ$81.11 M | -23.51% |
| 2011 | NZ$0.10 B | -18.23% |
| 2010 | NZ$0.12 B | -6.31% |
| 2009 | NZ$0.13 B | -16.47% |
| 2008 | NZ$0.16 B | 149.39% |
| 2007 | NZ$66.44 M | 73.83% |
| 2006 | NZ$38.22 M | 357.09% |
| 2005 | NZ$8.36 M | 39.49% |
| 2004 | NZ$5.99 M |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 | NZ$4.34 M | -99.89% | 🇺🇸 USA |
 | NZ$24.68 B | 531.69% | 🇺🇸 USA |
 | NZ$3.30 B | -15.40% | 🇺🇸 USA |
 | NZ$1.23 B | -68.28% | 🇺🇸 USA |
 | N/A | N/A | 🇺🇸 USA |
 | NZ$89.89 B | 2,200.55% | 🇨🇭 Switzerland |
 | NZ$83.35 B | 2,033.24% | 🇫🇷 France |
 | NZ$28.75 B | 635.82% | 🇮🇱 Israel |